Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.340
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors
October 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
2 Top Healthcare Stocks That Could Be Bought Out in 2022
↗
October 16, 2021
These two novel-drug makers could be top takeover targets next year.
Via
The Motley Fool
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review
↗
October 15, 2021
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields.
Via
Investor's Business Daily
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
↗
October 15, 2021
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Via
The Motley Fool
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
October 14, 2021
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend...
Via
FinancialNewsMedia
50 Biggest Movers From Yesterday
↗
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
↗
October 12, 2021
Crispr is planning to begin a registrational test in the first quarter of 2022.
Via
Investor's Business Daily
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
↗
October 12, 2021
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed ...
Via
Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
↗
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
35 Biggest Movers From Friday
↗
October 11, 2021
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for...
Via
Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
↗
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets...
Via
Talk Markets
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
↗
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...
Via
Benzinga
Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher
↗
October 08, 2021
Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, gaining 0.13% to 4,405.69. The U.S. has the...
Via
Benzinga
Topics
Stocks
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
↗
October 08, 2021
The broader market was mixed on Friday.
Via
The Motley Fool
Topics
Stocks
Why Allogene Therapeutics Stock Is Getting Hammered Today
↗
October 08, 2021
A possible safety issue is crushing the biotech's shares today.
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 08, 2021
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge
↗
October 08, 2021
Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, dropping 0.08% to 4,396.09. The U.S. has the...
Via
Benzinga
Topics
Stocks
Where Allogene Therapeutics Stands With Analysts
↗
October 08, 2021
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:
Via
Benzinga
28 Stocks Moving In Friday's Mid-Day Session
↗
October 08, 2021
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil...
Via
Benzinga
Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September
↗
October 08, 2021
Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also rose, gaining 0.16% to 4,406.93. The U.S. has...
Via
Benzinga
Topics
Economy
Stocks
Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021
↗
October 08, 2021
Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Friday
↗
October 08, 2021
Barclays cut the price target on Constellation Brands, Inc. (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 08, 2021
Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR...
Via
Benzinga
18 Stocks Moving in Friday's Pre-Market Session
↗
October 08, 2021
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine...
Via
Benzinga
Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well
↗
October 08, 2021
The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO)...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
August 20, 2021
Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 175.07% to $17.33 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 277....
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
↗
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
↗
September 24, 2021
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
↗
August 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
